1. Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS40.4620.649>37.60++++ CTPX72.910+++1.625++>4.31++++ SBX6,51.728++0.075>22.14++++ ALSKX110.7520.2593.214+++ AOX101.0580.5693.712+++ TTX64.817+++7.62++++1.850+ GKAMX41.525++1.535++1.328+ TPMX130.1830.2721.336+ TSX pr14,50.3710.6740.857 KPDX60.9470.2860.568 Supplementary Information Table 1 Table 1. The classification of human osteosarcoma xenografts response to chemotherapeutic drugs Abbreviations: TD, Tumor doubling time; SGD, Specific growth delay; T/C%, Maximal growth inhibition.

2. Table 2. Expression analysis of miRNAs in osteosarcoma xenografts treated with high dose Doxorubicin, Cisplatin and Ifosfamide Doxorubicin (DOX) Fold change Cisplatin (CPT) Fold Change Ifosfamide (IFO) Fold change hsa-miR-21710.0hsa-miR-34b29.1hsa-miR-327.4 hsa-miR-380-5p6.5hsa-miR-17-3p28.8hsa-miR-302a5.3 hsa-miR-1886.1hsa-miR-302d4.8hsa-miR-3785.0 hsa-miR-99a5.2hsa-miR-3404.3hsa-miR-5244.9 hsa-miR-3295.1hsa-miR-3294.2hsa-miR-526b3.7 hsa-miR-1405.0hsa-miR-135a3.4hsa-miR-3383.4 hsa-miR-3404.9hsa-miR-2173.3hsa-miR-1403.3 hsa-miR-369-5p3.7hsa-miR-5443.1hsa-miR-30e-5p2.7 hsa-miR-30a-3p3.6hsa-miR-128b2.8hsa-miR-135a2.7 hsa-miR-526b3.5hsa-miR-181c2.6hsa-miR-1872.7 hsa-miR-5053.4hsa-miR-5062.6hsa-miR-3742.7 hsa-miR-4313.3hsa-miR-1402.5hsa-miR-517a2.5 hsa-miR-3012.6hsa-miR-2112.4hsa-miR-2102.2 hsa-miR-3422.3hsa-miR-5052.3hsa-miR-92.1 hsa-miR-4912.2hsa-miR-542-5p2.3hsa-miR-15b2.1 hsa-miR-3372.1hsa-miR-3742.3hsa-miR-2232.1 hsa-miR-3301.9hsa-miR-4312.0hsa-miR-18a2.0 hsa-miR-221.8hsa-miR-1861.9hsa-miR-485-5p2.0 hsa-miR-302c0.4hsa-miR-5451.9hsa-miR-5142.0 hsa-miR-3380.4hsa-miR-3421.8hsa-miR-20a1.9 hsa-miR-3780.4hsa-miR-1510.5hsa-miR-199b1.9 hsa-miR-1910.5hsa-miR-4831.9 hsa-miR-90.4hsa-miR-515-3p1.9 hsa-miR-10a0.4hsa-miR-516-3p1.9 hsa-miR-20b0.4hsa-miR-5211.9 hsa-miR-485-5p0.4hsa-miR-280.4 hsa-miR-1870.3hsa-miR-2170.4 hsa-miR-517a0.3hsa-miR-4310.2 hsa-miR-515-5p0.2 hsa-miR-5240.2 hsa-miR-18a0.1 Supplementary Information Table 2

3. CharacteristicsFrequencyPercentage (%) Age (years) Mean (range)62 (30-93) Gender Male1458.3 Female1041.7 Anatomic site Ascending colon312.5 Transverse colon28.3 Descending colon416.7 Sigmoid colon312.5 Rectum1250.0 Histology Adenocarcinoma24100 UICC stage I416.7 II416.7 III833.3 IV833.3 Table 3. Characteristics of the 24 colon cancer patients Supplementary Information Table 3

4. Supplementary Information Figure 1 53- 21- 50- -p53 -p21 miR control miR-140 U-2 OS MG63 kDa miR control miR-140 -  -Tubulin

5. Supplementary Information Figure 2 ** 0h 24h MTX 0h 24h MTX kDa 53- 50- -p53 -  -Tubulin

6. -HDAC4 -  -Tubulin HCT 116 (wt-p53) vehicle control siRNA control siHDAC4 140- 50- kDa a b Supplementary Information Figure 3 HCT 116 (wt-p53)

7. Supplementary Information Figure 4 P=0.04